FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594221674> ?p ?o ?g. }

• W2594221674 endingPage "27952" @default.
• W2594221674 startingPage "27943" @default.
• W2594221674 abstract "// Xi Chen 1, * , Guangying Qi 2, 4, * , Mingqun Qin 3, * , Yantao Zou 1 , Kanghua Zhong 1 , Ying Tang 1 , Yong Guo 1 , Xinxiang Jiang 3 , Lihua Liang 3 , Xianqiong Zou 1 1 College of Biotechnology, Guilin Medical University, Guilin 541100, Guangxi, P. R. China 2 Department of Pathology and Physiopathology, Guilin Medical University, Guilin 541004, Guangxi, P. R. China 3 Department of Stomatology, Affiliated Hospital of Guilin Medical University, Guilin 541004, Guangxi, P. R. China 4 Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541004, Guangxi, P. R. China * These authors contributed equally to this work Correspondence to: Xianqiong Zou, email: xianqiongzou2009@yahoo.com Keywords: CAMP, LL-37, OSCC, DNA methylation, promoter Received: September 01, 2016      Accepted: February 20, 2017      Published: March 02, 2017 ABSTRACT LL-37, the active product of human cathelicidin antimicrobial peptide (CAMP) has a broad spectrum of antibacterial activity. LL-37 also has important physiological functions in immune regulation, angiogenesis and in modulating apoptosis. The roles of LL-37 in oral squamous cell carcinoma (OSCC) are still not clear. The correlation between DNA methylation and human CAMP expression is also unknown. Here human CAMP/LL-37 expression was assessed by immunohistochemistry in normal and OSCC tissues. The results indicated that low expression of CAMP/LL-37 correlated with histological differentiation and lymph node metastasis and also promoted tumor progression. A cell-specific methylation pattern in the promoter region of human CAMP was detected. Treatment with 5-aza-2’-deoxycytidine, a DNA demethylation reagent can increase human CAMP expression in epithelial cancer cells. The reporter assay showed that unmethylated human CAMP promoter activity was significantly higher than methylated promoter activity. Taken together, these results suggested that human CAMP/LL-37 might act as a tumor-suppressor in OSCC and DNA methylation might play roles during carcinogenesis via directly downregulating human CAMP promoter activity." @default.
• W2594221674 created "2017-03-16" @default.
• W2594221674 creator A5006335525 @default.
• W2594221674 creator A5008171524 @default.
• W2594221674 creator A5008601653 @default.
• W2594221674 creator A5015835149 @default.
• W2594221674 creator A5030543541 @default.
• W2594221674 creator A5035902781 @default.
• W2594221674 creator A5042951826 @default.
• W2594221674 creator A5053601883 @default.
• W2594221674 creator A5056835620 @default.
• W2594221674 creator A5066455905 @default.
• W2594221674 date "2017-03-02" @default.
• W2594221674 modified "2023-10-15" @default.
• W2594221674 title "DNA methylation directly downregulates human cathelicidin antimicrobial peptide gene <i>(CAMP)</i> promoter activity" @default.
• W2594221674 cites W1843201724 @default.
• W2594221674 cites W1853873243 @default.
• W2594221674 cites W1926715793 @default.
• W2594221674 cites W1934491273 @default.
• W2594221674 cites W1963922571 @default.
• W2594221674 cites W1967069761 @default.
• W2594221674 cites W1972181361 @default.
• W2594221674 cites W1972561912 @default.
• W2594221674 cites W1995237680 @default.
• W2594221674 cites W1997866877 @default.
• W2594221674 cites W2000049370 @default.
• W2594221674 cites W2006181612 @default.
• W2594221674 cites W2023703768 @default.
• W2594221674 cites W2026545058 @default.
• W2594221674 cites W2027489564 @default.
• W2594221674 cites W2031204755 @default.
• W2594221674 cites W2038616013 @default.
• W2594221674 cites W2041396033 @default.
• W2594221674 cites W2054708057 @default.
• W2594221674 cites W2078587242 @default.
• W2594221674 cites W2123032740 @default.
• W2594221674 cites W2124025109 @default.
• W2594221674 cites W2143967303 @default.
• W2594221674 cites W2146662359 @default.
• W2594221674 cites W2164015729 @default.
• W2594221674 cites W2166389246 @default.
• W2594221674 cites W2171215089 @default.
• W2594221674 cites W2212327748 @default.
• W2594221674 cites W2255227380 @default.
• W2594221674 doi "https://doi.org/10.18632/oncotarget.15847" @default.
• W2594221674 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5438620" @default.
• W2594221674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28427192" @default.
• W2594221674 hasPublicationYear "2017" @default.
• W2594221674 type Work @default.
• W2594221674 sameAs 2594221674 @default.
• W2594221674 citedByCount "18" @default.
• W2594221674 countsByYear W25942216742018 @default.
• W2594221674 countsByYear W25942216742019 @default.
• W2594221674 countsByYear W25942216742020 @default.
• W2594221674 countsByYear W25942216742021 @default.
• W2594221674 countsByYear W25942216742022 @default.
• W2594221674 countsByYear W25942216742023 @default.
• W2594221674 crossrefType "journal-article" @default.
• W2594221674 hasAuthorship W2594221674A5006335525 @default.
• W2594221674 hasAuthorship W2594221674A5008171524 @default.
• W2594221674 hasAuthorship W2594221674A5008601653 @default.
• W2594221674 hasAuthorship W2594221674A5015835149 @default.
• W2594221674 hasAuthorship W2594221674A5030543541 @default.
• W2594221674 hasAuthorship W2594221674A5035902781 @default.
• W2594221674 hasAuthorship W2594221674A5042951826 @default.
• W2594221674 hasAuthorship W2594221674A5053601883 @default.
• W2594221674 hasAuthorship W2594221674A5056835620 @default.
• W2594221674 hasAuthorship W2594221674A5066455905 @default.
• W2594221674 hasBestOaLocation W25942216741 @default.
• W2594221674 hasConcept C104317684 @default.
• W2594221674 hasConcept C136449434 @default.
• W2594221674 hasConcept C150194340 @default.
• W2594221674 hasConcept C190727270 @default.
• W2594221674 hasConcept C203014093 @default.
• W2594221674 hasConcept C204232928 @default.
• W2594221674 hasConcept C2777379352 @default.
• W2594221674 hasConcept C33288867 @default.
• W2594221674 hasConcept C41091548 @default.
• W2594221674 hasConcept C4937899 @default.
• W2594221674 hasConcept C502942594 @default.
• W2594221674 hasConcept C54355233 @default.
• W2594221674 hasConcept C71924100 @default.
• W2594221674 hasConcept C86803240 @default.
• W2594221674 hasConcept C8891405 @default.
• W2594221674 hasConcept C89423630 @default.
• W2594221674 hasConceptScore W2594221674C104317684 @default.
• W2594221674 hasConceptScore W2594221674C136449434 @default.
• W2594221674 hasConceptScore W2594221674C150194340 @default.
• W2594221674 hasConceptScore W2594221674C190727270 @default.
• W2594221674 hasConceptScore W2594221674C203014093 @default.
• W2594221674 hasConceptScore W2594221674C204232928 @default.
• W2594221674 hasConceptScore W2594221674C2777379352 @default.
• W2594221674 hasConceptScore W2594221674C33288867 @default.
• W2594221674 hasConceptScore W2594221674C41091548 @default.
• W2594221674 hasConceptScore W2594221674C4937899 @default.
• W2594221674 hasConceptScore W2594221674C502942594 @default.
• W2594221674 hasConceptScore W2594221674C54355233 @default.
• W2594221674 hasConceptScore W2594221674C71924100 @default.

• next